FRANÇAIS PREVIOUS PAGE NEXT PAGE SUBSCRIBE

TreatmentUpdate

TreatmentUpdate is CATIE's flagship treatment digest on cutting-edge developments in HIV/AIDS research and treatment. ( 8 issues per year.)

Expand list of issues | Collapse list of issues

TU 176 2010 January PDF
		I ANTI-HIV AGENTS - A. Massive change in U.S. treatment guidelines NEW
		I ANTI-HIV AGENTS - B. Earlier initiation of therapy recommended NEW
		I ANTI-HIV AGENTS - C. Considering delaying the start of therapy NEW
		I ANTI-HIV AGENTS - D. What to use for initial therapy NEW
		I ANTI-HIV AGENTS - E. Simplifying therapy NEW
		I ANTI-HIV AGENTS - F. What not to use NEW
		I ANTI-HIV AGENTS - G. Acute HIV infection—should it be treated? NEW
		I ANTI-HIV AGENTS - H. Reducing the risk of HIV transmission NEW
		I ANTI-HIV AGENTS - I. Hepatitis C virus co-infection NEW
		I ANTI-HIV AGENTS - J. Treatment-experienced patients NEW
TU 175 2009 November PDF
		I COMPLICATIONS AND SIDE EFFECTS: A. Inflammation and HIV
		I COMPLICATIONS AND SIDE EFFECTS: B. French study unexpectedly uncovers role of substance use in heart attacks
		I COMPLICATIONS AND SIDE EFFECTS: C. VA study fingers kidney disease as a major predisposing factor for heart attacks
		I COMPLICATIONS AND SIDE EFFECTS: D. BICOMBO study looks at the safety of abacavir
		I COMPLICATIONS AND SIDE EFFECTS: E. Cardiovascular risk and HIV treatment
TU 174 2009 July/August PDF
		I SIDE EFFECTS AND COMPLICATIONS: A. The kidneys
		I SIDE EFFECTS AND COMPLICATIONS: B. Drugs and the kidneys
		I SIDE EFFECTS AND COMPLICATIONS: C. HIV and the kidneys – a look over time
		I SIDE EFFECTS AND COMPLICATIONS: D. Cystatin C for monitoring kidney health
		I SIDE EFFECTS AND COMPLICATIONS: E. Comparing viruses – HIV and hepatitis C in mostly men
		I SIDE EFFECTS AND COMPLICATIONS: F. The kidneys and hep C in women
		I SIDE EFFECTS AND COMPLICATIONS: G. Age, tenofovir and the kidneys
		I SIDE EFFECTS AND COMPLICATIONS: H. A large study looks at tenofovir and kidney health
TU 173 2009 May/June PDF
		I ANTI-HIV AGENTS: A. Maturation inhibitor reappears
		I ANTI-HIV AGENTS: B. Raltegravir (Isentress)
		I ANTI-HIV AGENTS: C. Raltegravir—results after two years
		I ANTI-HIV AGENTS: D. Raltegravir as initial therapy
		I ANTI-HIV AGENTS: E. Darunavir—favourable results after two years
		II CANCER: A. Concern about cancer risk with raltegravir
		II CANCER: B. Predicting who is at high risk for lymphoma
TU 172 2009 March/April PDF
		I ANTI-HIV AGENTS - A. The 16th CROI
		I ANTI-HIV AGENTS - B. When is it best to start HAART?
		I ANTI-HIV AGENTS - C. Should HAART begin right after an HIV diagnosis?
		I ANTI-HIV AGENTS - D. Atazanavir and raltegravir—an interesting combination
		I ANTI-HIV AGENTS - E. Are new drug boosters coming?
		I ANTI-HIV AGENTS - F. Gene therapy
		I ANTI-HIV AGENTS - G. A clinical trial of gene therapy for HIV
		II COMPLICATIONS AND SIDE EFFECTS - A. Falling rates of heart attacks
		II COMPLICATIONS AND SIDE EFFECTS - B. France: a large hospital database looks at heart attacks
		II COMPLICATIONS AND SIDE EFFECTS - C. The DAD study: a large European database looks at heart attacks
		II COMPLICATIONS AND SIDE EFFECTS - D. Putting heart attack risk into perspective
TU 171 2009 February PDF
		I ANTI-HIV AGENTS: A. The changing picture of HIV
		I ANTI-HIV AGENTS: B. HAART reduces inflammation in the blood but...
		I ANTI-HIV AGENTS: C. Treatment interruption uncovers HIV’s attack on the kidneys
		II SIDE EFFECTS AND COMPLICATIONS: A. HAART and the safety of the fetus
		II SIDE EFFECTS AND COMPLICATIONS: B. French study clears HAART of cancer link in kids
		II SIDE EFFECTS AND COMPLICATIONS: C. Risk of deformities very low in infants exposed to HAART
TU 170 2009 January PDF
		I. ANTI-HIV AGENTS: A. Starting therapy—looking back
		I. ANTI-HIV AGENTS: B. New evidence changes guidelines about when to start treatment
		I. ANTI-HIV AGENTS: C. A few reasons for starting therapy at CD4+ counts above 350 cells
		I. ANTI-HIV AGENTS: D. Unexpected dangers of drug holidays—the SMART study
		I. ANTI-HIV AGENTS: E. Why are drug holidays dangerous?
		I. ANTI-HIV AGENTS: F. Treatment interruption surprisingly does not reduce heart disease risk
		I. ANTI-HIV AGENTS: G. Reduced inflammation linked to survival
TU 169 2008 August/September PDF
		I ANTI-HIV AGENTS: A. Good news for HAART users
		II ANTI-CANCER AGENTS: A. Kaposi’s sarcoma—past and future
		II ANTI-CANCER AGENTS: B. More about KS
		II ANTI-CANCER AGENTS: C. KS in HIV negative men
		II ANTI-CANCER AGENTS: D. Liposomal chemo for KS
TU 168 2008 June/July PDF
		I CO-INFECTIONS: A. Coming up: updates on hepatitis C
		I CO-INFECTIONS: B. The growing problem of insulin resistance
		I CO-INFECTIONS: C. Risk factors for insulin resistance in hep C
		I CO-INFECTIONS: D. French study finds recovery from hep c blocked by insulin resistance
		I CO-INFECTIONS: E. Dangerous liaisons: risky sex, drugs and hep C
		I CO-INFECTIONS: F. Rapid liver damage after recent HCV co-infection
		I CO-INFECTIONS: G. Some good news about HAART and liver health
		I CO-INFECTIONS: H. Unexpected liver damage—is ddI to blame?
		I CO-INFECTIONS: I. The disturbing issue of HCV re-infection
		I CO-INFECTIONS: J. Predicting recovery from hep C
TU 167 2008 April/May PDF
		I NUTRITION: A. Chromium deficiency in HIV
		I NUTRITION: B. Can chromium supplements help body shape?
		II HORMONES: A. Ovaries—hormone troubles in some HIV positive women
		III CO-INFECTIONS: A. Hepatitis C virus—some background information
		III CO-INFECTIONS: B. Liver damage occurs early in hepatitis C infection
		III CO-INFECTIONS: C. Changes to fats and sugar in the blood because of hepatitis C
TU 166 2008 March PDF
		I ANTI-HIV AGENTS: A. Introduction
		I ANTI-HIV AGENTS: B. Controversial findings on abacavir and heart attacks
		I ANTI-HIV AGENTS: C. Lopinavir and ritonavir (Kaletra) tablets get tested
		I ANTI-HIV AGENTS: D. A note about clinical trials
		I ANTI-HIV AGENTS: E. The Castle study: lopinavir vs. atazanavir
		I ANTI-HIV AGENTS: F. Is PF-232798 a possible successor to maraviroc?
		I ANTI-HIV AGENTS: G. Receptor blocker (SCH 532706) enters clinical trials
		I ANTI-HIV AGENTS: H. Vicriviroc
		II PREVENTION: A. The elusive AIDS vaccine
		II PREVENTION: B. Swiss guidelines take a troubling turn
TU 165 2008 January PDF
		I ANTI-HIV AGENTS: A. Using only lopinavir/ritonavir (Kaletra)
		I ANTI-HIV AGENTS: B. A trial of Kaletra monotherapy
		I ANTI-HIV AGENTS: C. Considering monotherapy

Previous Next

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE

Privacy | Permission to reproduce | Funders

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.